Register Login

All Posts

ASH 2025 Highlight: Beyond Immunosuppression: Two New Ways to Treat ITP

David Kuter gave this presentation at ASH 2025: Immune thrombocytopenic purpura is now recognized as a disorder characterized by both reduced production and increased destruction—this understanding drives treatment selection toward achieving complete remission, rather than just disease suppression. Increase Platelet Production The latest TPO receptor agonist, hetrombopag, now in phase 3 trials, offers a direct […]
read more

November 2025 QQ Summary: Historic Coag Factor Nomenclature

Our November Quick Question summary about Stuart-Prower Factor, linked to a 2023 article by Dave McGlasson about coagulation factor nomenclature. The summary and McGlasson’s article attracted a comment from Dr. Emmanuel Favaloro, which described the nomenclature of traditional and current VWF activity assays.  Dr. Favaloro cited three open-access articles on this topic (click to obtain the […]
read more

11-8-25 AHA Presentation Records Successful Reduction of Anticoagulation in AFIB

Click here for the results of a “One month of clot prevention after a stent was as effective as a Year-long course for AFIB.” Research Highlights: A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who received […]
read more

An Illustrated Review of Hemophilia B.

Click here for the illustrated open-access review, Hermans C, Astermark J, Trakymienė SŠ, Jiménez-Yuste, V. Haemophilia B: an illustrative review of current challenges and opportunities.  Res Prac Thromb Haemostasis, 2025;9, 103229. Abstract Background Hemophilia B is a genetic bleeding disorder caused by a deficiency of clotting factor IX, which presents unique challenges in clinical management. […]
read more